Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

3.7%

1 terminated/withdrawn out of 27 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

26%

7 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed trials have results

Key Signals

12 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

11(47.8%)

Phase 3

7(30.4%)

Phase 2

3(13.0%)

Early Phase 1

2(8.7%)

23Total

Phase 1(11)

Phase 3(7)

Phase 2(3)

Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials

NCT05663710Phase 1Recruiting

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Role: collaborator

NCT06520345Phase 3Recruiting

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Role: lead

NCT07100730Phase 3Recruiting

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

Role: lead

NCT06044857Phase 1Recruiting

PSMA PET Response Guided SabR in High Risk Pca

Role: collaborator

NCT07197580Phase 3Recruiting

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

Role: lead

NCT07238322Active Not Recruiting

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Role: lead

NCT05450744Phase 1Recruiting

131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)

Role: lead

NCT07197645Phase 1Recruiting

Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain

Role: lead

NCT07052214Phase 3Recruiting

PSMA PET Combined With MRI for the Detection of PCa

Role: lead

NCT06655064Terminated

Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

Role: lead

NCT06090331Unknown

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Role: lead

NCT06447103Phase 2Recruiting

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Role: collaborator

NCT06743100Unknown

18F-Floretyrosine Expanded Access Program

Role: lead

NCT06750419Phase 3Recruiting

89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study

Role: lead

NCT05146973Phase 2Completed

External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)

Role: lead

NCT05847348Phase 3Recruiting

68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients